China Shenghuo Announces Restated Results For Full Year 2007 & First Quarter 2008, Reports Results For Second & Third Qu... (ase ingross margin percentage was primar...)

HOME >> MEDICINE >> NEWS

China Shenghuo Announces Restated Results For Full Year 2007 & First Quarter 2008, Reports Results For Second & Third Quarter 2008

Date:11/20/2008

ase in gross margin percentage was primarily due to the sales of other branded OTC products, which carry lower profit margins. Sales of these products were terminated at the end of the second quarter.

Net loss for the second quarter of 2008 was $1.54 million compared with net income of $1.32 million for the same period last year. Second quarter 2008 loss per diluted share was $0.08 compared to earnings per diluted share of $0.07 for the same period last year.

Third Quarter 2008 Financial Results

Revenues for the third quarter ended September 30, 2008 were $7.28 million, representing an increase of 73% compared to $4.20 million for the third quarter of 2007. The increase in sales was driven mainly by increased sales of the Company's main product, Xuesaitong Soft Capsules, augmented by increased sales of the OTC products, cosmetic products and increased export of products.

Third quarter 2008 gross profit was $5.31 million, an increase of 68% over $3.16 million for the same period in 2007. Gross margin for the third quarter of 2008 was 72.9%, compared with 75.3% for the third quarter of 2007. The decrease in gross margin percentage was driven largely by the increase in the cost of the raw material used in the Company's primary product.

Sales and marketing expenses for the third quarter of 2008 increased 93% to $2.99 million over $1.55 million in the third quarter of 2007, primarily due to the increase in commission paid to sales representatives due to increased sales of the Company's primary product and the increase in marketing expenses for the Company's cosmetic products. General and administrative expenses for the third quarter of 2008 increased to $1.82 million compared to $341,372 for the same quarter in 2007, primarily due to the increase in expenses related to the Company's status as a public company with its securities traded on a U.S. national exchange (including
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine news :

1. ChinaBio(R) Inaugural Partnering Forum Scheduled for June 2009 in Shanghai, China
2. China Documents First Case of Tick-Borne Disease Spread
3. Drug Information Association (DIA) Opens New Office In China
4. China Healthcare Acquisition Corp Agrees to Terminate Agreement to Acquire Europe Asia Huadu Environment Holding Pte, Ltd.
5. China Information Security Technology, Inc. Issues Guidance & Discuss Outlook for 2009
6. China Bio-Immunity Corporation to Report Third Quarter 2008 Financial Results
7. Pantheon China Acquisition Corp. to Acquire China Cord Blood Services Corporation - Extension Proxy Filed With SEC
8. Measles Initiative Supports Disease Prevention for Children in Chinas Earthquake Zone
9. China Sky One Medical, Inc. Announces Record Third Quarter 2008 Results
10. China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates
11. China Pharma Holdings, Inc. to Host Third Quarter 2008 Earnings Conference Call at 10 a.m. EST Friday November 7, 2008

Post Your Comments:

China Shenghuo Announces Restated Results For Full Year 2007 & First Quarter 2008, Reports Results For Second & Third Qu...(ase ingross margin percentage was primar...),Health